MedTrace Logo

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

NCT00664664 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 744

Last updated 2020-12-24

No results posted yet for this study

Summary

This study is designed to compare 2 doses of APD125 (20 mg and 40 mg) with placebo in otherwise healthy adults with primary insomnia primarily with complaints of maintaining sleep. Participants will be required to maintain a daily sleep dairy for up to 3 weeks while on study.

Conditions

  • Primary Insomnia

Interventions

DRUG

APD125

soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks

DRUG

APD125

soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks

DRUG

Placebo

soft gelatin capsule, daily dosing for up to 3 weeks

Sponsors & Collaborators

  • Arena Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Arena CT.gov Administrator · Arena Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664664 on ClinicalTrials.gov